Archives
-
Ferrostatin-1 in Ferroptosis Research: Evidence and Limits
2026-10-06
Ferrostatin-1 (Fer-1) is primarily a pharmacological research probe for examining lipid-peroxidation-sensitive cell death. This overview distinguishes its established mechanistic value from broader therapeutic claims, compares Fer-1 evidence with a 2025 fullerenol study in cisplatin-associated acute kidney injury, and outlines limitations involving specificity, model dependence, and translational relevance.
-
Deferiprone and Iron-Stress Biology: Evidence Overview
2026-10-05
Deferiprone, also known as 3-hydroxy-1,2-dimethylpyridin-4-one, is used in research to perturb cellular iron availability. The strongest supplied evidence comes from a 2025 IPEC-J2 enterocyte study linking iron deficiency with altered transcription, proliferation, inflammation, and metabolism, while iron excess produced a distinct metabolic profile. These findings support mechanistic research but do not establish clinical efficacy, universal anticancer activity, or direct relevance to human intestinal disease.
-
Thapsigargin in Calcium and ER Stress Research
2026-10-05
Thapsigargin is a widely used SERCA pump inhibitor for investigating intracellular calcium homeostasis, endoplasmic reticulum stress, and apoptosis. This overview compares supplier-reported properties with findings from a 2024 Autophagy study of metabolic stress, emphasizing what the evidence supports, where interpretation remains uncertain, and why model context limits broader conclusions.
-
Cyclic di-GMP in Biofilm and STING Research
2026-10-04
Cyclic di-GMP is an intracellular second messenger with distinct research relevance in bacterial biofilm biology and mammalian innate-immune studies. The strongest supplied evidence is a 2024 eLife report linking cyclic di-GMP to HipH, genome stability, and antibiotic persistence during biofilm development. Claims involving STING, cancer immunotherapy studies, or metastatic melanoma models require separate primary evidence and should not be inferred from the bacterial findings.
-
Epacadostat and IDO1: Research Context and Evidence
2026-10-03
Epacadostat (INCB024360) is an IDO1-focused research compound used to examine tryptophan–kynurenine biology and immune regulation. This overview distinguishes supplier-reported biochemical and cellular potency from findings in a standardized whole-blood immunometabolism protocol, evaluates conceptual applications in immuno-oncology research, and explains why these sources do not establish clinical efficacy or validate a specific PD-1/PD-L1 checkpoint inhibitor combination.
-
Ziprasidone HCl: From Impurity to Assay Design
2026-10-02
Ziprasidone HCl is more than a receptor pharmacology tool: its use in cancer metabolism research also depends on chemical identity, impurity control, and assay context. This evidence-led guide connects GOT1 inhibition with the practical quality lessons of modern ziprasidone characterization.
-
Ferrostatin-1: From Probe to Translation
2026-10-01
Ferrostatin-1 (Fer-1) is more than a rescue reagent: it is a mechanistic probe for lipid peroxidation-driven cell death. This article uses PFOS-induced injury in human renal cells to show how Fer-1 can strengthen ferroptosis assays, guide translational interpretation, and connect oxidative lipid damage inhibition with cancer biology research and neurodegenerative disease models.
-
OX40L mRNA: From Mechanism to Translation
2026-10-01
A translational framework for using mouse OX40L mRNA to separate transient ligand expression, OX40-dependent signaling, and functional T-cell outcomes, while placing aptamer-targeted mRNA findings in their proper evidentiary context.
-
Kaempferol, NF-κB/PTGS2, and Melanocyte Ferroptosis
2026-09-30
The 2026 reference study identifies an NF-κB/PTGS2-associated signaling axis that connects oxidative stress with ferroptotic melanocyte injury in vitiligo. Using RSL3-induced ferroptosis models, transcriptomics, network analysis, pathway inhibition, and lesional skin validation, the authors show that kaempferol suppresses lipid peroxidation and preserves melanocyte viability.
-
PERK Loss Sensitizes Colorectal Cancer to Ferroptosis
2026-09-30
The reference study identifies PERK as an adaptive regulator that preserves SLC7A11 expression during endoplasmic reticulum stress in colorectal cancer. By showing that PERK loss lowers ATF4-dependent SLC7A11 regulation, increases lipid peroxidation, and restricts tumor growth, the work connects unfolded protein response signaling with ferroptotic vulnerability.
-
Liproxstatin-1 Workflows for Ferroptosis Research
2026-09-29
Build more discriminating ferroptosis assays with Liproxstatin-1, from GPX4-deficient cell protection to oxidative-stress models. This practical guide connects lipid-peroxidation readouts, salivary-gland findings, renal injury workflows, and troubleshooting strategies.
-
PRDX6–GPX4 Control of Ferroptosis
2026-09-29
Hu et al. identify PRDX6 as a dual regulator of ferroptosis resistance: it removes oxidized phospholipids and promotes GPX4 relocation to membranes through a C47-dependent disulfide bond. The study shows that inhibiting PRDX6 alongside ferroptosis induction increases lipid peroxidation and suppresses tumor growth, providing a mechanistic framework for combination strategies.
-
Cy7 NHS Ester: Practical Labeling Guide
2026-09-28
Cy7 NHS ester is a water-soluble Sulfo-Cy7 NHS Ester reagent for labeling accessible amino groups on proteins and peptides when maintaining an aqueous, non-denaturing workflow is important. It is suited to near-infrared imaging and biomolecule conjugation, but it should not be used for targets lacking accessible amino groups or for long-term storage of prepared solutions.
-
Bi-Layer TXA Dressing for Hemostasis and Infection Control
2026-09-28
Nguyen and colleagues developed a bi-layer wound dressing combining tranexamic acid (TXA), the nitric oxide donor SNAP, and propolis to address clot stability and bacterial contamination in one material. Laboratory assays indicated early fibrin-network formation and substantial reductions in two bacterial species, supporting further investigation while leaving in vivo and clinical performance to be established.
-
Deracoxib: Separating COX-2 Inhibition from Inflammation
2026-09-27
Deracoxib is a selective COX-2 inhibitor whose effects should be interpreted through more than a single inflammatory marker. This article connects compound-specific assay design with a macrophage RNA-sequencing study, clarifying what that model can—and cannot—tell researchers about Deracoxib.